Episode Details
Back to EpisodesFDA To Review 12 Peptides: What It Means Moving Forward
Published 14 hours ago
Description
The FDA recently announced it will review the safety and efficacy of a number of powerful peptides. In 2023, based on safety concerns and reports that providers were treating patients irresponsibly, the FDA assigned a number of peptides for Category 2, effectively banning US pharmacies from compounding them. Today, Dr. Seeds addresses the why, the how, and the what’s next.
Learn more about SSRP Institute
Follow for more!
Instagram: @williamseedsmd | @redoxmedicalgroup
Youtube: Subscribe Here